Avacta: Avacta engages in the provision of proprietary solutions to the healthcare sector. Avacta is developing next-gen biologics to improve the clinical outcome for the sizable proportion of solid tumour patients having “cold” tumours that do not have a durable response to checkpoint inhibitors alone. Avacta is addressing this need by combining two proprietary platforms – Affimers®, a best-in-class antibody mimetic and TMACTM, drug conjugates that are activated in the tumour microenvironment to release pro-inflammatory drugs that synergise with the Affimer checkpoint modulators.
Healthcare/Medical Devices
Clinical Stage
Pre-Clinical Stage
Disease Space
Europe, Public
Market Cap
Therapeutic Modalities
Platform Technology
Unit 20, Ash Way
Thorp Arch Estate
Wetherby, LS23 7FA
United Kingdom

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

European Biotech Investor Day 2019

New York City, August 1, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.